On Wednesday, Prima Biomed Ltd. (NASDAQ:PBMD)’s shares declined -0.46% to $2.18.
Prima Biomed Ltd. (PBMD) saw its stock enhance exponentially Wednesday after data from its Phase II CAN-003 ovarian cancer clinical trial was released. Here’s a look at what its share enhance means for the company:
- At the end of the day Wednesday, Prima Biomed had risen over 268% since market opening, bumping the stock to trade at $5.90.
- The data from the trial was positive, which means that there was meaningful improvement in overall survival of second remission patients. The positive results also mean that the drug is working as predictable.
- Market reaction to the trial results are similar to positive data from other emerging biotech companies. Generally speaking, positive trials can make small cap stocks intriguing takeover targets for large cap firms in the same space.
- However, Prima Biomed lives in a very volatile industry, and it is still a pretty small company which can add to price volatility. Plus, let’s not forget that this is just the first step in what can be a very long process so more bumps could be in the road ahead.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
Humana Inc (NYSE:HUM)’s shares gained 0.90% to $214.38.
In an effort to improve patient care through improved population health administration, Rockford Health System and Humana Inc. (HUM) have established a new Accountable Care agreement for members throughout northern Illinois.
The agreement, effective May 1, 2015, will unite one of the country’s leading health and well-being companies and one of the region’s largest health systems in a common aim – to implement efficient health care delivery that improves wellness opportunities and lowers costs.
Established in 1883, the Rockford Health System comprises Rockford Memorial Hospital, Rockford Health Physicians, Visiting Nurses Association and the Rockford Memorial Development Foundation. The system also has a wide network throughout the region, counting 450 physicians on the medical staff, nearly 3,400 employees and more than 300 volunteers.
Humana recognizes the need to marry a physicians’ clinical expertise with business savvy to drive a cohesive integrated care approach. By partnering together with Rockford Health System on accountability, care moves from an episodic to a value-based model that improves costs, quality and the patient experience.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Employer Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.
At the end of Wednesday’s trade, Sanofi SA (ADR) (NYSE:SNY)‘s shares surged 2.37% to $50.60.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Legg Mason Inc (NYSE:LM), ended its Wednesday’s trading session with 0.15% gain, and closed at $53.85.
Legg Mason Inc (LM) stated preliminary assets under administration of $706.8 billion as of May 31, 2015. This month’s AUM comprised of preliminary long-term inflows of $1.7 billion, driven by fixed income inflows of $1.6 billion and equity inflows of $0.1 billion. Liquidity inflows were $1.0 billion. May flows comprised of the formerly revealed $1.0 billion equity funding. This month’s AUM comprised of $2.8 billion in negative foreign exchange impact.
Legg Mason is a global asset administration firm with $707 billion in assets under administration as of May 31, 2015. The Company provides active asset administration in many major investment centers throughout the world. Legg Mason is headquartered in Baltimore, Maryland, and its common stock is listed on the New York Stock Exchange (LM).
Legg Mason, Inc. is a publicly owned asset administration holding company. The firm provides investment administration and related services to institutional and individual clients, company-sponsored mutual funds and other pooled investment vehicles through its wholly owned auxiliaries. Legg Mason, Inc. was founded in 1899 and is based in Baltimore, Maryland.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
